CCDC88C::PDGFRB-rearranged myeloid neoplasm with predominant neutrophilia and rapid response to imatinib: a molecularly defined case report
Open Access
- 22 June 2026
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1855322
Abstract
Myeloid/lymphoid neoplasms with PDGFRB rearrangements are rare hematologic malignancies usually associated with eosinophilia and sensitivity to tyrosine kinase inhibitors, whereas atypical presentations remain poorly defined. We report a 60-year-old man with persistent leukocytosis and thrombocytopenia detected during a routine health examination. Bone marrow examination revealed marked granulocytic proliferation without increased blasts, and peripheral blood showed predominant neutrophilia with only mild eosinophilia. Cytogenetic analysis identified a t(5;14) translocation. RNA sequencing detected an in-frame CCDC88C exon 12::PDGFRB exon 11 fusion, and targeted sequencing additionally identified an ATM frameshift mutation. Treatment with low-dose imatinib (200 mg daily) led to rapid normalization of leukocyte counts within one week and sustained hematologic remission during follow-up. This case broadens the clinicopathologic spectrum of CCDC88C::PDGFRB -rearranged neoplasms and highlights the value of RNA sequencing in identifying actionable kinase fusions in atypical myeloproliferative presentations.Keywords
This publication has 11 references indexed in Scilit:
- Myeloproliferative Neoplasm With Eosinophilia Exhibiting a Rare GOLGA4-PDGFRB Rearrangement in an Infant: Navigating a Rare Malignancy Amidst Limited Pediatric GuidelinesJournal of Pediatric Hematology/Oncology, 2026
- Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genesLeukemia, 2025
- How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusionsBlood, 2025
- The Ataxia-telangiectasia mutated (ATM) is the most important gene for repairing the DNA in Myelodysplastic NeoplasmDNA Repair, 2025
- Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusionInternational Journal of Hematology, 2020
- Contemporary Classification and Diagnostic Evaluation of HypereosinophiliaAmerican Journal of Clinical Pathology, 2020
- Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion GeneActa Haematologica, 2019
- Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phaseAnnals of Hematology, 2017
- Myeloid neoplasms with eosinophiliaBlood, 2017
- Identification and functional characterization of imatinib‐sensitive DTD1‐PDGFRB and CCDC88C‐PDGFRB fusion genes in eosinophilia‐associated myeloid/lymphoid neoplasmsGenes, Chromosomes and Cancer, 2014